Market Overview

UPDATE: Jefferies Raises PT to $10 on Amedisys, Maintains Neutral on Reimbursement Uncertainty

Related AMED
Is Merge Healthcare A Buy After Strong Q3 Results?
Mid-Day Market Update: ON Semiconductor Surges On $1 Billion Buyback Plan; POZEN Shares Slip

Jefferies maintained Amedisys (NASDAQ: AMED) with a Hold and raised the price target from $9.00 to $10.00.

Jefferies analyst Brian Tanquilut wrote, "We continue to have a cautious view on AMED given our belief that ongoing budget discussions in DC could yield incremental rate cuts for home nursing providers such as AMED. Additionally, we are concerned that ongoing volume pressure (from persistent weakness in recertifications) will impact AMED's ability to offset upcoming rate cuts and drive LT EPS growth."

Amedisys closed at $11.19 on Wednesday.

Latest Ratings for AMED

DateFirmActionFromTo
Oct 2014JefferiesMaintainsHold
Oct 2014Credit SuisseMaintainsUnderperform
Jul 2014Credit SuisseMaintainsUnderperform

View More Analyst Ratings for AMED
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (AMED)

Around the Web, We're Loving...

Get Benzinga's Newsletters